GU CONNECT has developed new content on the clinical impact of PARP inhibitors in prostate cancer for the ESMO OncologyPRO portal website, to address recent scientific and clinical insights that have been published.
In this GU CONNECT podcast series international experts, Assoc. Prof. Tanya Dorff and Dr Phillip Koo, from the field of GU Oncology and Nuclear Medicine discuss the latest developments in the field of radiopharmaceuticals and their use in Prostate Cancer. They are also joined by guest speaker Dr Neal Shore.
Our faculty of international experts, Prof. Alexander Drzezga (Germany), Assoc. Prof. Alicia Morgans (USA) and Prof. David Pfister (Germany) discuss the current opinions on managing nmCRPC and the implications of new imaging modalities.
We recently delivered a virtual Experts Knowledge Share meeting discussing the Current opinions on managing nmCRPC and the implications of new imaging modalities.
Dr Ray Manneh Kopp takes a look at the highlights of 2020 from GU CONNECT, in particular the new trials and practice changing developments in prostate, urothelial and kidney cancer, as well as the impact of COVID-19 on existing treatments and protocols.
Assoc. Prof. Alicia Morgans MD, MPH summarises the recent interactive Prostate Cancer Management Masterclass that she co-hosted, along with Dr. Neal Shore, MD, FACS, Assoc. Prof. Tanya Dorff, MD and Prof. Evan Yu, MD
GU CONNECT has developed an accredited interactive e-learning, slide set and short informative videos to help you confidently and quickly apply the SHARE Communication Framework and move towards even better patient conversations.
As a result of the success of the Experts Knowledge Share meeting during ESMO 2019, GU CONNECT has turned the educational programme into an interactive e-learning. Watch the video and then take the e-learning for your CME credit.
Dr. Phillip J. Koo provides his thoughts on the use of advanced PET imaging in prostate cancer.
This month Prof. Sandy Srinivas and Dr. Roberto Iacovelli provide their thoughts and views on: Adjuvant Therapy in mRCC.
GU cancer update by Dr. Elena Castro, Hospital Universitario Virgen de la Victoria, Málaga, Spain.
GU CONNECT has summarised the highlights from ESMO 2020 for you
GU CONNECT has summarised the highlights from ASCO for you.
GU CONNECT has summarised highlights of the recent ASCO GU 2020 meeting for you.
GU CONNECT has summarised highlights of the recent ESMO 2019 meeting for you.
GU CONNECT has summarised the highlights from ASCO 2019 for you
GU CONNECT has summarised the highlights of the recent ASCO GU 2019 meeting for you.
GU CONNECT has summarised the highlights from ESMO 2018 for you.
GU CONNECT has summarised the highlights of the recent ASCO GU 2018 meeting for you.
GU CONNECT has summarised the highlights of ESMO September 2017 for you along with the other CONNECT groups.
Please submit your clinical topic for the next GU CONNECT newsletter here.
GU CONNECT expert, Dr. Neal Shore, MD, FACS provides his perspective on treatment sequence for mCRPC after intensified therapy in mCSPC.
GU CONNECT expert, Prof. Gert De Meerleer, MD, PhD provides his perspective on the management of oligometastatic prostate cancer.
GU CONNECT expert, Dr Fabio Schutz, MD provides his perspective on optimising patient selection and treatment options for metastatic castration-sensitive prostate cancer.
GU CONNECT expert, Prof. Sandy Srinivas, MD discusses maintenance therapy for metastatic urothelial cancer, and in particular the practice changing clinical trial JAVELIN 100.
Prof. Steven Joniau, MD, PhD provides an overview of nmCRPC and highlights of the SPARTAN, PROSPER and ARAMIS trials including the recent overall survival update and discusses the safety and quality of life data.
Our GU CONNECT experts, Dr Daniel Keizman (Israel), Prof Gert Attard (UK), Dr Neal Shore (USA), Dr Elena Castro (Spain) and Dr Roberto Iacovelli (Italy) provide their thoughts and opinions on the challenging topic of the role and place of genetic testing in prostate cancer.
Dr. Daniel Keizman discusses the strategies for optimal bone health management in patients with prostate cancer.
Prof. Sandy Srinivas, Stanford University Medical Center, California, USA, takes a look at antibody-drug conjugates (ADCs) in urothelial cancer.
Dr. Fabio Schutz addresses a key challenge when treating patients with metastatic castration resistant prostate cancer (mCRPC). What do you do if they progress on an androgen receptor (AR) directed therapy?
Dr. Roberto Iacovelli brings to you his interpretation of the data when deciding upon the best approach to treatment sequencing in mRCC.